Is RVMD a good stock to buy? We came across a bullish thesis on Revolution Medicines, Inc. on Two Natural Capital’s Substack. In this article, we will summarize the bulls’ thesis on RVMD. Revolution Medicines, Inc.’s share was trading at $93.21 as of March 26th.
Photo by National Cancer Institute on Unsplash
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. RVMD is advancing a differentiated approach to targeting RAS-driven cancers, an area that has historically challenged drug development due to the difficulty of inhibiting protein-protein interactions and the lack of clear binding sites on RAS proteins.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
RAS mutations are among the most common oncogenic drivers across lung, colorectal, and especially pancreatic cancers, yet their biology—particularly the tight binding of GTP/GDP and the predominance of the active RAS(ON) state in tumors—has limited therapeutic progress. Earlier breakthroughs such as Sotorasib and Adagrasib marked important progress by selectively targeting KRAS G12C mutations through covalent binding in the inactive RAS(OFF) state, but their scope remains limited by mutation specificity, resistance development, and indirect targeting of the active oncogenic state.
Revolution Medicines is addressing these limitations by developing novel small molecules that directly target RAS(ON) through a molecular glue mechanism. Its lead candidates, daraxonrasib (a pan-RAS inhibitor) and zoldonrasib (a G12D-selective inhibitor), form a tri-complex with Cyclophilin A and RAS(ON), effectively blocking downstream signaling.
This approach enables broader mutation coverage, including the highly prevalent G12D mutation in pancreatic ductal adenocarcinoma, while maintaining a manageable safety profile due to transient pathway inhibition that allows normal cells to recover. Early data, particularly in second-line metastatic pancreatic cancer, suggest meaningful clinical activity in a setting with limited treatment options.
With a growing late-stage pipeline and potential expansion into earlier lines of therapy and additional tumor types, Revolution Medicines is positioned at the forefront of next-generation RAS targeting. Its innovative platform, combined with strong clinical momentum and strategic focus on high-unmet-need indications, underpins a compelling long-term growth opportunity and reinforces the company’s premium valuation.
